Drago R. Sliskovic - Concepedia

Author

Drago R. Sliskovic

Also Known As

D. R. SLISKOVIC, D. R. Sliskovic, D. Robert Sliskovic, D.R Sliskovic, D.R. Sliskovic, D.Robert Sliskovic, Drago R Sliskovic, Drago R. Sliskovic, Drago Robert Sliskovic, Drago Sliskovic

Publications

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)Time Warner (United States)Warner University

About

Drago R. Sliskovic is an author at Pfizer (United States) specializing in pharmacology, medicine, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	14	667
2	Biochemistry	13	13	612
3	Natural Sciences	7	7	316
4	Engineering	2	2	60
5	Health Sciences	2	2	53

Drago R. Sliskovic

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Matrix Metalloproteinase Inhibition Attenuates Left Ventricular Remodeling and Dysfunction in a Rat Model of Progressive Heart Failure Janet T. Peterson, Hussein Hallak, Linda K. Johnson, Circulation	2001	301
Inhibitors of cholesterol biosynthesis. 3. Tetrahydro-4-hydroxy-6-[2-(1H-pyrrol-1-yl)ethyl]-2H-pyran 2-one inhibitors of HMG-CoA reductase. 2. Effects of introducing substituents at positions three and four of the pyrrole nucleus Bruce D. Roth, C. John Blankley, Alexander Chucholowski, Journal of Medicinal Chemistry	1991	183
Structure−Activity Relationships and Pharmacokinetic Analysis for a Series of Potent, Systemically Available Biphenylsulfonamide Matrix Metalloproteinase Inhibitors Patrick O’Brien, Daniel F. Ortwine, A.G. Pavlovsky, Journal of Medicinal Chemistry Pharmaceutical ScienceBioorganic ChemistryEffective Mmp InhibitorsPharmacotherapyChemical Biology	2000	97
Inhibitors of Acyl-CoA:Cholesterol <i>O</i>-Acyl Transferase (ACAT) as Hypocholesterolemic Agents. CI-1011: An Acyl Sulfamate with Unique Cholesterol-Lowering Activity in Animals Fed Noncholesterol-Supplemented Diets Helen T. Lee, Drago R. Sliskovic, Joseph A. Picard, Journal of Medicinal Chemistry Lipid DisorderAcyl SulfamateBiochemistryUnique Cholesterol-lowering ActivityHypocholesterolemic Agents	1996	93
Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: Comparison with selected HMG-CoA reductase inhibitors Thomas Bocan, Erika Ferguson, W. McNally, Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism Nonhepatic Sterol SynthesisHmg-coa Reductase InhibitorsHepatologyMedicineLiver Physiology	1992	86
Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation Thomas Bocan, Sandra Bak Mueller, Edie Quenby Brown, Atherosclerosis OxysterolBiochemistryMedicineAntiatherosclerotic ActivityCholesterol-fed Rabbits	1994	80
Inhibitors of cholesterol biosynthesis. 1. trans-6-(2-Pyrrol-1-ylethyl)-4-hydroxypyran-2-ones, a novel series of HMG-CoA reductase inhibitors. 1. Effects of structural modifications at the 2- and 5-positions of the pyrrole nucleus Bruce D. Roth, Daniel F. Ortwine, M. L. HOEFLE, Journal of Medicinal Chemistry	1990	70
Inhibitors of cholesterol biosynthesis. 2. 1,3,5-Trisubstituted [2-(tetrahydro-4-hydroxy-2-oxopyran-6-yl)ethyl]pyrazoles Drago R. Sliskovic, Bruce D. Roth, Marina Wilson, Journal of Medicinal Chemistry	1990	63
Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase Mary Kay Shaw, Roger S. Newton, Drago R. Sliskovic, Biochemical and Biophysical Research Communications HepatologyBiochemistryHmg-coa ReductaseLiver PhysiologyNatural Sciences	1990	54
Inhibitors of cholesterol biosynthesis. 4. trans-6-[2-(Substituted-quinolinyl)ethenyl/ethyl]tetrahydro-4-hydroxy-2H-pyran-2-ones, a novel series of HMG-CoA reductase inhibitors Drago R. Sliskovic, J. A. PICARD, W. Howard Roark, Journal of Medicinal Chemistry	1991	53

Page 1